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S U M M A R Y
Objectives: To assess the risk factors for recurrence of septic arthritis with an emphasis on the duration of
antibiotic treatment, to gather data for a prospective study on an optimized antibiotic treatment in
adults with septic arthritis.
Methods: This was a retrospective single-center study conducted for the period 1996–2008.
Results: A total of 169 episodes of septic arthritis in 157 adult patients (median age 63 years; 65 females)
were included. In 21 episodes (21/169, 12%), arthritis recurred after the end of antibiotic treatment.
Multivariate analysis showed that Gram-negative infection (odds ratio (OR) 5.9, 95% conﬁdence interval
(CI) 1.4–25.3), immune suppression (OR 5.3, 95% CI 1.3–22.0), and lack of surgical intervention were
associated with recurrence. The size of the infected joint, the number of surgical drainages (OR 1.3, 95% CI
1.0–1.7), arthrotomy vs. arthroscopic drainage (OR 0.5, 95% CI 0.2–1.8), duration of antibiotic therapy
(OR 1.0, 95% CI 0.95–1.05), and duration of intravenous antibiotic therapy (OR 1.0, 95% CI 1.0–1.0) were
not. Seven days of intravenous therapy had the same success rate as 8–21 days (OR 0.4, 95% CI 0.1–1.7)
and >21 days (OR 1.1, 95% CI 0.4–3.1). Fourteen days or less of total antibiotic treatment had the same
outcome as 15–28 days (OR 0.4, 95% CI 0.1–2.3) or >28 days (OR 0.4, 95% CI 0.1–1.6).
Conclusions: In this retrospective study of adults with septic arthritis, the duration of antibiotic therapy,
or an early switch from intravenous to oral administration, did not statistically inﬂuence the risk of
recurrence. Due to study limitations, the data cannot be used directly for antibiotic therapy
recommendations for septic arthritis. Prospective randomized trials are warranted to optimize the
antibiotic treatment of septic arthritis.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Septic arthritis is a surgical as well as a medical emergency.1–4
Although no studies have been published comparing drainage to
non-drainage procedures, experts would probably recommend
joint drainage, as this condition represents a closed abscess.1–5 The
optimal antibiotic treatment remains controversial since random-
ized controlled studies, at least in adults, are lacking.6We also have§ This manuscript was presented in part at the 20th European Congress of Clinical
Microbiology and Infectious Diseases, Vienna, Austria, April 12, 2010; the 70th
Annual Congress of the Swiss Orthopedic Society, St. Gallen, Switzerland, July 2,
2010; and the Joint Annual Meeting of the Swiss Society for Infectious Diseases,
Swiss Society for Hospital Hygiene, and the Swiss Society for Intensive Care
Medicine, Lausanne, Switzerland, September 3, 2010.
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1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2011.12.019yet to determine whether interdigital arthritis and large size joint
arthritis should be treated differently. Different antibiotic regi-
mens have been recommended, such as 2 weeks intravenous (IV)
therapy for streptococci, 3–4 weeks IV for staphylococci and Gram-
negative bacteria,7,8 and more than 4 weeks for immune
suppressed patients or abnormal joints, e.g., severe osteoarthritis.7
Others recommend parenteral treatment for 2 weeks, followed by
another 2 weeks of oral treatment;5,9 or for 4 weeks without
indicating the means of administration.6 Outpatient antibiotic
therapy (OPAT) services have been developed in the USA and
Europe to maintain parenteral treatment. In addition, many
surgeons prescribe antimicrobials for longer periods without
further justiﬁcation.1,4
Parenteral medication should be limited as far as possible.10We
hypothesize that if surgical drainage is adequately performed,
septic arthritis could theoretically be treated with oral antibiotics
and for shorter periods of time than reported in the literature.ses. Published by Elsevier Ltd. All rights reserved.
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determined the risk factors for recurrence and sequelae. This
retrospective study was not designed to draw direct conclusions
regarding antibiotic use in septic arthritis. Therefore our data
should not be considered as any form of recommendation
regarding the duration or administration route of antibiotic
therapy in this neglected ﬁeld of research.
2. Methods
2.1. Setting
The Orthopedic Service of Geneva University Hospitals has 135
acute care beds and a dedicated infectious diseases (ID) special-
ist.11 Lavage for any septic arthritis is usually performed on
admission as a surgical emergency. In severe infection or an
unfavorable course (clinical and biological),12 a surgical re-
intervention is performed according to the decision of the
responsible surgeon. The choice of antibiotic agents and the
duration of their administration depend on the surgeon and the ID
physician in charge of the individual patient.
2.2. Data collection
The Laboratory of Bacteriology and the hospital’s Administra-
tive Coding Ofﬁce databases were retrospectively searched for
adult native joint arthritis during the period January 1996 to
December 2008. Forty-two variables for each episode were
assessed pertaining to demographic characteristics, immune
suppression, microbiology, surgical and antibiotic treatment,
and outcomes. A surgeon (LT) and a physician (IU) independently
recorded each variable on an Excel spreadsheet. In the case of
discordance, a consensus was negotiated.
Patients were followed-up until December 31, 2010, i.e., 3 years
after the inclusion of the last patient. The study was approved by
the Hospital’s ethics committee (No. 08-017R). No informed
consent was requested.
2.3. Microbiology procedures
Aspirate material from suspected infected joints was cultured
using microbiology procedures that were unchanged during the
study period; these procedures were based on the Clinical and
Laboratory Standards Institute (CLSI) guidelines.13 To enhance
speciﬁcity, only cultures positive on agar plates with signiﬁcant
growth were considered. Growth in enrichment broth was ignored.
2.4. Inclusion criteria and deﬁnitions
The deﬁnition of an infectious arthritis required the presence of
intra-articular pus and a surgical and antibiotic treatment targeted
to joint infection. Culture-negative septic arthritis cases were
included because their omission would introduce a substantial
selection bias. Bacteremia was deﬁned as a documented positive
blood culture with the same pathogen as that of the arthritis in
cases where blood cultures had been sampled before the antibiotic
treatment. Patients with an abscess in the surrounding soft tissue
were included if the abscess could be excised or drained in toto
during the ﬁrst surgical intervention.
2.5. Exclusion criteria
Patients with the following conditions were excluded: arthritis
due to other reasons, e.g., rheumatoid arthritis, crystal-induced
arthropathy (even in the presence of concomitant infection),
patients known or diagnosed during follow-up for rheumaticpolyarthritis or other autoimmune diseases, patients with an
episode of respiratory or gastrointestinal infection in the past 2
months (possibility of reactive arthritis) or gout, viral arthritis,
preexisting implant material in the infected joint, and amputation
as the primary therapeutic approach. Finally, infections with
pathogens for which the literature suggests long-lasting antibiotic
treatments or does not indicate surgical drainage were excluded:
tuberculosis, other mycobacteria, fungi,14 brucellosis,15 borrelio-
sis,16 gonococcal arthritis,17 nocardiosis,18 and Mycoplasma spp.
Also excluded were cases of secondary arthritis due to an
underlying infection for which a total antibiotic treatment of
more than 2 weeks is recommended: endocarditis, Lemierre’s
syndrome,19 spondylodiscitis,20 or suspected osteomyelitis21
outside the joint wall.
2.6. Subgroup analyses
Two separate subgroup analyses for large joint arthritis and
arthritis due to Staphylococcus aureus were added to the general
analyses. Large joints were deﬁned as: hip, knee, shoulder,
sternoclavicular, sacroiliac, and the ankle joints.
2.7. Clinical outcomes
Cure was deﬁned as complete clinical, laboratory, and
microbiological resolution of arthritis after a minimum active
follow-up time of 6 weeks following the end of antibiotic
treatment.
Recurrence was deﬁned as new clinical signs of infection with
the same microorganism 2 weeks or more after the end of
treatment for the ﬁrst episode. Sequelae were persisting non-
infectious handicaps (debilitating pain, limitation of joint move-
ments) that were not resolved despite adequate physiotherapy and
analgesia. The sequelae were not pre-existing and had to be
attributed to the infection.
2.8. Statistical analyses
Group comparisons were performed using the Pearson Chi-
square test or the Wilcoxon rank sum test. Logistic regression with
cluster control (random effect) was used to determine associations
with the outcomes recurrence and sequelae. Each of these analyses
was separately repeated for the subgroups of large joint arthritis
and arthritis due to S. aureus. Independent variables with a p-value
of 0.05 in the univariate analysis were introduced stepwise into a
multivariate analysis. Exceptions were variables for surgical
interventions and antibiotic treatment, which were automatically
included in the ﬁnal model. We included 6–10 predictor variables
per outcome event.22 Key variables were checked for collinearity
and interaction, the latter by interaction terms and Mantel–
Haenszel estimates. According to these criteria, included variables
were: joint type, immune suppression, pathogens, number of
surgical interventions, duration of IV antibiotic treatment, and
duration of total antibiotic therapy. All remained in the ﬁnal model.
We intended to analyze duration of antibiotic treatment
variables within three strata (instead of dichotomous variables)
in order to reveal more details. The strata of the categorical
variables were around the median value, with inferior and superior
limits relying on the 33% and 66% percentiles, rounded up to
clinically practical duration times. According to this approach, the
total duration of antibiotic therapy was divided into the following
three strata: 0–14 days, 15–28 days, and more than 28 days. This
approach was similar for parenteral antibiotic therapy with the
strata 0–7 days, 8–21 days, and more than 21 days.
We assessed a possible linearity of the duration of antibiotic
administration and recurrence of infection by linear and logistic
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performed ﬁrst with untransformed antibiotic duration variables,
and repeated with quadratic and logarithmic (ln) transformations
of these variables. Furthermore, we investigated the presence of a
potential threshold beneath which the duration of antibiotic
administration could be associated with an enhanced risk of
recurrence by graphical plotting of all recurrent cases in relation to
their antibiotic duration.
p-Values of 0.05 (two-tailed) were considered signiﬁcant.
STATA software (9.0, STATA, USA) was used.
3. Results
3.1. Patients
A total of 212 native joint arthritis episodes were found. Of
these, 43 were excluded due to loss to follow-up (n = 4);
amputation (n = 22); secondary arthritis due to spondylodiscitis
(n = 6), Lemierre’s syndrome (n = 1), pneumonia (n = 1), or
endocarditis (n = 2); and arthritis due to tuberculosis (n = 1), other
mycobacteria (n = 2), Nocardia sp (n = 1), Brucella sp (n = 1),
Neisseria meningitidis (n = 1), or Mycoplasma sp (n = 1).
A total of 169 arthritis episodes in 157 patients (median age 63
years, interquartile range (IQR) 39–78 years; 65 females) remained
in the ﬁnal analysis. In 65 episodes (65/169, 38%), patients were
immunocompromised: diabetes mellitus (n = 34), steroid medica-
tion (n = 22), HIV disease (n = 4), and solid organ transplantation
(n = 5).
3.2. Infected joints
One-hundred ﬁfty-nine arthritis episodes involved a single
joint, seven involved two joints, and three involved three joints.
There were 126 episodes (126/169, 75%) of large joint arthritis andTable 1
Characteristics and comparisons between large joint and interdigital joint arthritis (all
Large joint arthritis
(hip, knee, shoulder, 
(n = 126)
Patients
Female sex 44 (35%) 
Median age, years 58 
Single joint infection 118 (94%) 
Immune suppressionb 49 (39%) 
Diabetes mellitus 23 (18%) 
Origin of arthritis
Drug abuse 16 (13%) 
Ulcer/wound 4 (3%) 
Surgical site/intra-articular injection 24 (19%) 
Infection
Maximal median C-reactive protein, mg/l 191 
Staphylococcus aureus 67 (53%) 
Gram-negative pathogens 23 (18%) 
Surgical treatment
Lack of any surgical intervention 3 (2%) 
Median number of surgical interventions 2 
Arthrotomy compared to arthroscopy 87 (69%) 
Resectionc compared to arthroscopy 10 (8%) 
Antibiotic treatment
Median duration of antibiotic treatment, days 42 
Median duration of intravenous treatment, days 14 
Outcomes
Recurrence of infection 12 (10%) 
Deﬁnite sequelae at long-term follow-up 29 (23%) 
Median length of hospital stay, days 22 
a Only signiﬁcant p-values 0.05 (two-tailed) are displayed.
b Immune suppression: diabetes mellitus, steroids, organ transplantation, and HIV d
c Resection: excision arthroplasty, arthrodesis, or other orthopedic surgery not limit43 episodes (43/169, 25%) of interdigital joint arthritis (Table 1).
The large joints included: knee (n = 51), hip (n = 21), shoulder
(n = 32), ankle (n = 9), sternoclavicular (n = 2), elbow (n = 2), and
sacroiliac joints (n = 1). Interdigital arthritis involved the following
joints: metatarsophalangeal (n = 23), interphalangeal (n = 18),
Lisfranc (n = 1), and cuneometatarsal (n = 1).
3.3. Origin of infection and documented bacteremia
For 58 arthritis episodes (58/169, 34%), the focus of infection
could not be determined. The remaining 111 causes were:
traumatic (n = 31), surgical site infection after ligament surgery
or intra-articular steroid injections (n = 31), intravascular drug
abuse (n = 16), wound infections (n = 20), and hematogenous
seeding from remote infections (n = 13). For the episodes with
iatrogenic or traumatic cause, the median delay between the
event and the onset of symptomatic arthritis was 14 days (IQR
2–41 days). Half of the patients had documented bacteremia (46
episodes positive out of 97 episodes with blood cultures
sampled).
3.4. Pathogens
There were 130 episodes involving Gram-positive bacteria
(130/169, 77%) and 26 involving Gram-negative bacteria (26/169,
15%). In 18 episodes (18/169, 11%) no pathogen could be identiﬁed.
Ten patients had mixed Gram-positive and Gram-negative
infections. Eighty-eight episodes (88/169, 52%) were due to S.
aureus, of which 17 were methicillin-resistant strains (MRSA).
Community-acquired MRSA was not encountered. Thirty-eight
episodes (38/169, 22%) were due streptococci: S. pyogenes (n = 13),
S. agalactiae (n = 7), and others. Escherichia coli (n = 5) and
Pseudomonas aeruginosa (n = 5) were the most frequent Gram-
negative pathogens. types of arthritis, N = 169)
ankle)
Interdigital joint arthritis
(foot and hand)
(n = 43)
Comparison, p-valuea
21 (49%)
71
41 (95%)
16 (37%)
11 (26%)
0 (0%) 0.014
16 (37%) 0.001
7 (16%)
50 0.001
21 (49%)
3 (7%)
6 (14%) 0.004
1 0.008
22 (51%)
14 (33%) 0.001
36 0.001
6 0.001
9 (21%)
15 (35%)
18
isease.
ed to drainage.
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All but nine patients (9/169, 5%) underwent a surgical
intervention, with a median delay of 7 days after the onset of
infection (IQR 2–15 days). In 87 episodes (87/169, 51%), patients
underwent a single drainage, in 39 episodes (39/169, 23%) two
drainages, and in the remaining cases between three and 13
interventions. Surgical re-intervention occurred after a median
delay of 3 days (IQR 2–8 days). In 27 episodes (27/160, 17%),
surgical drainage was arthroscopic, in 109 episodes (109/160, 68%)
by arthrotomy, and in 24 episodes (24/160, 15%) arthrotomy with
resection or arthrodesis.
3.6. Antibiotic treatment
All patients received systemic antibiotic therapy. No anti-
biotics were added to the irrigating solutions. The duration and
the choice of antibiotic agents were not changed by the different
ID consultants over the study period (Chi-square tests; p > 0.2).
For 18 episodes (18/169, 11%), antibiotic treatment was
empirical.
3.7. Choice of antibiotic agents
For parenteral therapy, ﬂucloxacillin, amoxicillin/clavulanic
acid, and glycopeptides were the most frequently prescribed
agents, and ciproﬂoxacin/rifampin (22 episodes, 13%) for oral
treatment. Quinolones were used alone or in combination in 64
episodes (38%), clindamycin in 43 (25%), co-trimoxazole in nine
(5%), and linezolid in ﬁve episodes (3%). In 32 staphylococcal
infections (32/88, 36%), rifampin was used in combination therapy.
Oral treatment consisted of beta-lactam antibiotics in only 24
episodes (24/169, 14%).Table 2
Characteristics and comparison of the patient groups with cure, recurrence, and seque
Recurrence
(n = 21)
Non-recurre
(n = 148)
Patients
Female sex 7 (33%) 58 (39%) 
Median age, years 71 62 
Large size joint arthritisb 12 (57%) 114 (77%) 
Immune suppressionc 15 (71%) 50 (34%) 
Diabetes mellitus 8 (38%) 26 (18%) 
Organ transplantation 3 (14%) 2 (1%) 
Infection
Maximal median C-reactive protein, mg/l 118 172 
Documented bacteremia 8 (38%) 38 (26%) 
Gram-positive pathogens 10 (48%) 120 (81%) 
Staphylococcus aureus 8 (38%) 80 (54%) 
Methicillin-resistant S. aureus 5 (24%) 12 (8%) 
Gram-negative pathogens 7 (33%) 19 (13%) 
Surgical treatment
Lack of any surgical intervention 5 (24%) 4 (3%) 
Median number of surgical interventions 2 1 
Arthrotomy compared to arthroscopy 11 (52%) 98 (66%) 
Resectiond compared to arthroscopy 1 (5%) 23 (16%) 
Antibiotic treatment
Median duration of antibiotic treatment, days 42 42 
Median duration of intravenous antibiotic
treatment, days
10 14 
Empirical antibiotic treatment 4 (19%) 14 (9%) 
Outcome
Median length of hospital stay, days 16 22 
NA, not applicable.
a Only signiﬁcant p-values 0.05 (two-tailed) are displayed.
b Large joints: hip, knee, shoulder, sternoclavicular, and the ankle joints.
c Immune suppression: diabetes mellitus, steroids, organ transplantation, and HIV d
d Resection: excision arthroplasty, arthrodesis, or other orthopedic surgery not limit3.8. Duration of antibiotic treatment
The median duration of total antibiotic therapy was 6
weeks; 12 episodes were treated for 14 days (12/169, 7%), 26
episodes for between 15 and 28 days (26/169, 15%), and 131
episodes for >28 days (131/169, 78%). The patient groups
receiving total short (14 days) or long-term (>28 days)
antibiotic treatments did not differ substantially in demo-
graphic or surgical characteristics, ﬁnal outcomes, or joint type
(Tables 1 and 2).
The median duration of parenteral therapy was 14 days; 65
episodes (65/169, 38%) were treated IV for a maximum of 7 days,
46 episodes (46/169, 27%) for between 8 and 21 days, and 58
episodes (58/169, 34%) for >21 days. All patients treated for <14
days had IV therapy throughout. Documented bacteremic infec-
tions were treated parenterally for longer than non-bacteremic
episodes (median 22 days vs. 7 days, p = 0.002).
3.9. Outcomes
3.9.1. Cure and follow-up time
A total of 104 episodes (104/169, 62%) were cured without
sequelae. Whether or not sequelae occurred could not be
determined in 21 cases. The median follow-up time was 3.6 years
(IQR 1.5–6.0 years). There were no secondary infections following
arthritis among the study patients.
3.9.2. Recurrence of infection and sequelae
Twenty-one patients revealed a recurrent arthritis (21/169,
12%) after a median delay of 71 days. Of these, 12 (12/126, 10%)
concerned large joint episodes and nine (9/43, 21%) interdigital
joint arthritis (p = 0.05). Among the nine patients without surgical
intervention, ﬁve showed recurrence (5/9, 56%).lae after native joint arthritis (all types of arthritis, N = 169)
nce Comparison,
p-valuea
Non-sequelae
(n = 125)
Sequelae
(n = 44)
Comparison,
p-valuea
44 (35%) 13 (30%)
62 61
0.050 81 (65%) 29 (66%)
0.001 18 (14%) 25 (57%) 0.001
0.029 13 (10%) 13 (30%) 0.003
0.001 0 (0%) 1 (2%)
172 154
33 (26%) 13 (30%)
0.001 87 (70%) 30 (68%)
54 (43%) 23 (52%)
0.025 15 (12%) 5 (11%)
0.015 17 (14%) 8 (18%)
0.000 NA NA
0.019 1 2
79 (63%) 20 (45%) 0.040
6 (5%) 18 (41%) 0.000
42 42
14 10
10 (8%) 8 (18%)
22 26
isease.
ed to drainage.
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(n = 4), arthrodesis (n = 3), limitation of mobility (n = 3), amputa-
tion due to functional impairment (n = 2), secondary osteoarthritis
(n = 1), and persistent pain at last follow-up (n = 31). Among the
nine patients without surgical intervention, two had sequelae (2/9,
22%).
3.10. Multivariate analyses of risk factors for adverse outcomes
3.10.1. Recurrence of infection
In the multivariate analysis, lack of surgical intervention was
the most important risk factor for recurrence (odds ratio (OR) 21.9,
95% conﬁdence interval (CI) 2.07–333.9), followed by Gram-
negative arthritis (OR 5.9, 95% CI 1.4–25.3) and immune
suppression (OR 5.3, 95% CI 1.3–22.0) (Table 3). The ﬁnal model
was more than acceptable with a non-signiﬁcant goodness-of-ﬁt
test and a receiver operating curve (ROC) value of 0.87 (95% CI
0.78–0.96).
No antibiotic-related parameters revealed a statistical associa-
tion with recurrence: 7 days of IV therapy had the same effect as
8–21 days (OR 0.4, 95% CI 0.1–1.7) and >21 days of IV treatment
(OR 1.1, 95% CI 0.4–3.1); 14 days of total antibiotic treatment had
the same outcome as 15–28 days (OR 0.4, 95% CI 0.1–2.3) and >28
days (OR 0.4, 95% CI 0.1–1.6). We failed to detect linearity or a
threshold level for antibiotic duration and risk of recurrence.
3.10.2. Subgroups of large joint arthritis and arthritis due to S. aureus
The same trends were noted in a sub-analysis for large joint
arthritis, but the variables did not reach formal statistical
signiﬁcance (Table 3). The separate analysis of the subgroup of
S. aureus arthritis was not different from the global analysis. While
immune suppression was again revealed as a signiﬁcant risk factor
(OR 3.4, 95% CI 1.2–10.4), 7 days of IV therapy had the same effect
as 8–21 days (OR 0.4, 95% CI 0.1–1.8) and as >21 days of IV
treatment (OR 1.6, 95% CI 0.5–5.1), and 14 days of total antibioticTable 3
Predictors of recurrence in all type of arthritis and large joint arthritis (random-effect 
Univariate analysis:
All arthritis
Multi
All ar
OR (95% CI) OR (9
Female sex 0.8 (0.3–2.0) 
Age 1.0 (1.0–1.0) 
Hip joint 0.3 (0.1–2.2) 
Knee joint 1.3 (0.5–3.3) 
Shoulder joint 0.4 (0.1–1.8) 
Ankle joint 0.9 (0.1–7.3) 
Lack of surgical intervention 11.3 (2.7–46.2) 21.9 (
Number of surgical interventions 1.2 (1.0–1.4) 1.3 (1
Arthrotomy compared to arthroscopy 0.5 (0.2–1.8) 
Resectionb 0.2 (0.1–1.8)
Duration of total antibiotic treatment 1.0 (1.0–1.0) 1.0 (1
15–28 days compared to 14 days 0.4 (0.1–2.3) 0.4 (0
>28 days compared to 14 days 0.4 (0.1–1.6) 0.1 (0
Total duration of intravenous therapy 1.0 (1.0–1.0) 
8–21 days compared to 7 days 0.4 (0.1–1.7) 0.7 (0
>21 days compared to 7 days 1.1 (0.4–3.1) 1.2 (0
Total duration of oral antibiotics 1.0 (Refer
Empirical antibiotic treatment 2.3 (0.7–7.6) 
Immune suppressionc 3.6 (1.3–9.9) 5.3 (1
Steroid medication 1.1 (1.1–1.2) 
Organ transplantation 12.2 (1.9–77.8) 
Staphylococcus aureus 0.6 (0.2–1.6) 
Methicillin-resistant S. aureus 4.2 (1.3–14.1) 
Gram-negative pathogens 4.2 (1.4–12.5) 5.9 (1
OR, odds ratio; CI, conﬁdence interval; NA, not applicable due to substantial interactio
a Large joints: hip, knee, shoulder, sternoclavicular, and the ankle joints.
b Resection: excision arthroplasty, arthrodesis, or other orthopedic surgery not limit
c Immune suppression: diabetes mellitus, steroid medication, organ transplantation,treatment was similar to 15–28 days (OR 0.4, 95% CI 0.1–3.6) and
>28 days (OR 0.4, 95% CI 0.1–2.2).
3.10.3. Sequelae
In the multivariate analysis, only resection (OR 7.9, 95% CI 1.2–
54) and immune suppression (OR 3.6, 95% CI 1.5–8.7) were
associated with sequelae. No antibiotic-related parameters inﬂu-
enced sequelae (Table 4). The same trends were observed for large
size joint arthritis compared to interdigital arthritis. The variables
did not reach statistical signiﬁcance (data not shown).
4. Discussion
We report our experience in the management of 169 episodes of
septic native joint arthritis in patients hospitalized in an
orthopedic service. The minimum clinical follow-up was long,
recurrence occurred in only 12% of the cases, and the ﬁnal
statistical model was accurately adapted.
A lack of surgical intervention revealed a 21-times higher risk of
recurrence than at least one surgical intervention. None of the
other surgical parameters analyzed was associated with a risk of
recurrence. This is congruent with the orthopedic literature
indicating no differences between arthroscopy and arthrotomy
for the initial drainage of knee,2 hip,23 and other joint septic
arthritis.4,24 We could not determine any ideal antibiotic duration.
Antibiotic-related ORs and corresponding 95% CIs were often
around one, indicating no difference. Thus, 7 days of IV therapy
had the same effect as >21 days of IV treatment; also a maximum
14 days of antibiotic treatment had the same outcome as >28 days.
Of note, all our patients received antibiotic medication. Hence we
are unable to estimate a recurrence risk with surgery alone. The
total duration of antibiotic treatment had no inﬂuence on the risk
of recurrence, in contrast to parameters that are inherent to patient
baseline characteristics, such as immune suppression.9,25 While
age and diabetes mellitus did not inﬂuence outcome, steroidcontrolled logistic regression)
variate analysis:
thritis
Univariate analysis:
Large joint arthritisa
Multivariate analysis:
Large joint arthritisa
5% CI) OR (95% CI) OR (95% CI)
NA
NA
NA
NA
NA
NA
2.07–333.9) 5.1 (0.4–60.7)
.0–1.7) 1.2 (1.1–1.5) 1.4 (1.1–1.8)
0.5 (0.1–1.7)
.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
.1–5.8) NA
.1–1.6) NA
1.0 (1.0–1.1) 1.0 (1.0–1.1)
.1–5.1) 0.4 (0.1–4.1) 0.8 (0.1–18.5)
.5–6.2) 2.4 (0.6–9.8) 4.3 (0.5–41.1)
ence) 1.0 (Reference)
1.4 (0.2–12.4)
.3–22.0) 4.5 (1.2–17.7) 14.3 (1.2–176.2)
1.1 (1.0–1.1)
10.3 (0.6–175.8)
0.4 (0.1–1.4)
4.6 (1.0–21.0)
.4–25.3) 6.4 (1.7–23.2) 5.8 (1.2–28.1)
n.
ed to drainage.
 and HIV disease.
Table 4
Predictors of sequelae in native joint arthritis (random-effect controlled logistic
regression)
Univariate
analysis
Multivariate
analysis
OR (95% CI) OR (95% CI)
Female sex 0.65 (0.3–1.2)
Age 1.0 (1.0–1.0)
Recurrence of infection 3.8 (1.1–12.6)
Delay infection onset to ﬁrst surgery 1.0 (1.0–1.0)
Lack of any surgical intervention 2.4 (0.3–17.4) 0.9 (0.1–13.3)
Number of surgical interventions 1.1 (0.9–1.3) 1.2 (1.0–1.5)
Arthrotomy compared to arthroscopy 0.8 (0.2–2.3)
Resectiona compared to arthroscopy 8.5 (2.1–33.6) 7.9 (1.2–54)
Duration of total antibiotic treatment 1.0 1.0
15–28 days compared to 14 days 0.3 (0.1–1.5) 0.4 (0.1–4.4)
>28 days compared to 14 days 0.2 (0.1–1.0) 0.3 (0.1–2.4)
Total duration of intravenous therapy 1.0 (0.9–1.0)
8–21 days compared to 7 days 1.0 (0.4–2.3)
>21 days compared to 7 days 0.4 (0.2–1.0)
Immune suppressionb 2.8 (1.3–5.8) 3.6 (1.5–8.7)
Steroid medication 1.0 (0.9–1.1)
Staphylococcus aureus 1.2 (0.6–2.6)
Methicillin-resistant S. aureus 1.8 (0.5–6.7)
Gram-negative pathogens 2.0 (0.8–5.7)
Large joint arthritisc 0.5 (0.2–1.1)
OR, odds ratio; CI, conﬁdence interval.
a Resection: excision arthroplasty, arthrodesis, or other orthopedic surgery not
limited to drainage.
b Immune suppression: diabetes mellitus, steroid medication, organ transplan-
tation, and HIV disease.
c Large joints: hip, knee, shoulder, sternoclavicular, and the ankle joints.
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predictors of recurrence.
The lack of inﬂuence of the different antibiotic modalities was
equally noted in the subpopulation of patients with large weight-
bearing joint arthritis compared to interdigital arthritis, and for S.
aureus infections. There were no differences including or excluding
interdigital arthritis. Studies on antibiotic modalities in interdigital
septic arthritis are rare,3,26 and the literature does not provide any
data proving that interdigital septic arthritis would be different to
treat than large joint arthritis.
Synovial penetration of antibiotic agents during parenteral
administration is good.27 Recent retrospective data suggest that
regimens with an early switch to oral antibiotics with good
bioavailability are as effective as prolonged parenteral regimens,
at least for staphylococcal osteomyelitis.28,29 For bone infections,
several antibiotic agents already have proven clinical efﬁcacy:
quinolones,30 linezolid,31 clindamycin,32 fusidic acid,29,30 com-
bined with rifampin.29,30 These drugs have an oral bioavailability
of over 90%.32 Studies of septic arthritis in children have revealed
that a short IV treatment is successful.6 Prado et al. reported that
in 70 children with osteoarticular infections (60% septic
arthritis), a regimen of 7 days initial IV antibiotic treatment,
followed by 3–5 weeks of oral treatment was sufﬁcient for
cure.33 Kim et al. compared short and longer durations of
antibiotic therapy among 20 children. Less than 10 days of
parenteral treatment for Gram-positive hip arthritis was sufﬁ-
cient after surgical drainage.34 Peltola et al. recommended a 10-
day course of antimicrobial treatment in a randomized trial
comparing 10 days (including a short-term IV therapy) to 30
days for childhood arthritis.35 Jagodzinski et al. prospectively
showed that 3 days of high-dose IV therapy followed by 3 weeks
of oral medication cured 70 children.36 As in our study, an early
conversion from parenteral to oral antibiotics after a median of 7
days was equally effective in the treatment of pediatric arthritis
among 186 children.37 This cut-off of 7 days was also conﬁrmed
in another trial where 7 vs. 14 days of parenteral antibioticsshowed an equal outcome after surgical drainage in 130 cases
with infectious arthritis.38
For adults, Angly et al. investigated 31 operated patients with
interdigital arthritis of the hands. No recurrence of infection
occurred after surgery and antibiotics administered for a median of
2 days IV and a median of 17 days orally.26
While Gram-negative bacilli are seen in 9–17% of cases of
infectious arthritis,39 the outcome from such infections is
reported as good in the older literature. We cannot explain our
considerable recurrence risk in this subgroup, besides the fact that
we found only 26 episodes, which may be too small a number to
allow a conclusion to be drawn. Gram-negative osteoarticular
infection is also a hallmark of immune suppression.3 Therefore it
is possible that immune suppression might be a confounding
factor with underlying disease. The mean duration of antibiotic
therapy for our Gram-negative episodes was 42 days, and we
doubt that a prolonged treatment would change the risk of
recurrence.
Sequelaeintermsoffunctionalimpairmentwereobservedin26%
of cases, similar to the studies of Ross et al. with 26% sequelae9 and
Vispo-Seara et al. with 20% sequelae in arthritis patients.4 In the
regressionanalysis,noantibioticorclinicalparameterwasfoundto
be signiﬁcantly associated with sequelae. Indeed, the literature
suggeststhatcartilagedamagemaybethemostimportantfactorfora
poor functional outcome.4,26 Cartilage damage itself was signiﬁ-
cantlycorrelatedwithatimedelaylongerthan2weeksbetweenthe
onset of infection and surgery.4However we could not conﬁrm this
statistical association.
Our study has several limitations: (1) It was a retrospective,
single-center study with a heterogeneous patient population and
a small sample size. (2) The subgroup analyses, e.g., for S. aureus
infections or large size joint arthritis, further diminished the
sample size. Thus, our results should be interpreted only as a
trend, helping to design future prospective randomized trials.
We wish to emphasize that our pilot data should not be
considered as any form of recommendation regarding the
duration or administration route of antibiotic therapy. (3) We
included all arthritis cases according to the inclusion criteria, i.e.,
large and small joints, together with the 18 patients without
microbiological documentation of arthritis. Excluding them
would have introduced a selection bias to everyday clinical life.
Indeed, statistical analyses failed to show any signiﬁcant
differences in the outcome of small and large joint native
arthritis. However, for future prospective trials regarding
optimal antibiotic therapy, the separation of small and large
joint arthritis cases is necessary. (4) We cannot exclude
therapeutic decision bias; e.g. the patients who were doing well
could be those who had short antibiotic courses. (5) Patients
with recurrences treated in another hospital may have been
undetected. However, since the Geneva University Hospitals is
by far the largest and only public hospital in the area, we
consider the possibility very low.
In conclusion, our pilot data, based on a retrospective study
with a heterogeneous adult study population, failed to reveal an
enhanced recurrence risk regarding the duration of antibiotic
therapy, or an early switch from IV to oral administration.
Prospective randomized trials are needed to optimize antibiotic
treatment in patients with septic arthritis.
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